The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

NHS Foundation Trust

Status and phase: Completed; Phase 1

Conditions: Heart Failure

Treatments: Drug: Glucagon-Like Peptide 1

Study type: Interventional

Funder types: Other

Identifiers

NCT02129179

PO1860

Details and patient eligibility

About

This study aims to assess the effect of glucagon-like peptide-1 on cardiac output and transpulmonary gradient in patients undergoing right heart catheterisation for clinical reasons.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age over 18
• Able to give informed consent
• On the waiting list for heart transplant
• Left Ventricular Dysfunction awaiting catheterisation

Exclusion criteria

• Nicorandil, glibenclamide, Dipeptidyl Peptidase-4 inhibitor, Glucagon-Like Peptide-1 receptor agonist or insulin
• Women of child bearing age and breast feeding women
• Cardiac pacemaker or other implanted metallic device
• Unable to give informed consent

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

GLP-1

Experimental group

Treatment:

Drug: Glucagon-Like Peptide 1